Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W J Sandborn

Showing results (11-20 of 186) with videos related to

Pageof 19
Sort By:
Inflammatory Bowel Diseases|March 10, 2001
Infliximab for the treatment of orofacial Crohn's diseaseU Mahadevan, W J Sandborn
Inflammatory Bowel Diseases|May 25, 1999
Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safetyW J Sandborn, S B Hanauer
Contemporary Internal Medicine|March 9, 1995
Drug therapy for inflammatory bowel diseaseE V Loftus, W J Sandborn
Current Gastroenterology Reports|November 18, 2000
Clinical pharmacology of inflammatory bowel disease therapiesW J Sandborn, W A Faubion
Gut|May 13, 2004
Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel diseaseW J Sandborn, E V Loftus
Drugs of Today (Barcelona, Spain : 1998)|March 11, 2004
Drug therapy of inflammatory bowel diseaseL J Egan, W J Sandborn
Alimentary Pharmacology & Therapeutics|April 14, 2006
Systematic review: the management of pouchitisD S Pardi, W J Sandborn
Mayo Clinic Proceedings|May 13, 1999
Practice guidelines for inflammatory bowel disease: an instrument for assessmentW J Tremaine, W J Sandborn
Alimentary Pharmacology & Therapeutics|December 21, 2002
Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitisW J Sandborn, S B Hanauer
Alimentary Pharmacology & Therapeutics|August 5, 2003
Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithmW J Sandborn, B G Feagan
Pageof 19

Showing results (11-20 of 186) with videos related to

Sort By:
Pageof 19
Inflammatory Bowel Diseases|March 10, 2001
Infliximab for the treatment of orofacial Crohn's diseaseU Mahadevan, W J Sandborn
Inflammatory Bowel Diseases|May 25, 1999
Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safetyW J Sandborn, S B Hanauer
Contemporary Internal Medicine|March 9, 1995
Drug therapy for inflammatory bowel diseaseE V Loftus, W J Sandborn
Current Gastroenterology Reports|November 18, 2000
Clinical pharmacology of inflammatory bowel disease therapiesW J Sandborn, W A Faubion
Gut|May 13, 2004
Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel diseaseW J Sandborn, E V Loftus
Drugs of Today (Barcelona, Spain : 1998)|March 11, 2004
Drug therapy of inflammatory bowel diseaseL J Egan, W J Sandborn
Alimentary Pharmacology & Therapeutics|April 14, 2006
Systematic review: the management of pouchitisD S Pardi, W J Sandborn
Mayo Clinic Proceedings|May 13, 1999
Practice guidelines for inflammatory bowel disease: an instrument for assessmentW J Tremaine, W J Sandborn
Alimentary Pharmacology & Therapeutics|December 21, 2002
Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitisW J Sandborn, S B Hanauer
Alimentary Pharmacology & Therapeutics|August 5, 2003
Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithmW J Sandborn, B G Feagan
Pageof 19